ArticlePloS one2009
Recurrent genomic gains in preinvasive lesions as a biomarker of risk for lung cancer.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 52 citations in OpenAlex.
- Association between the TP63 and CIR1 polymorphisms and non-small cell lung cancer in Chinese population.Journal of cardiothoracic surgery · 2026Article
- Gene amplification in the premalignant stages of non-small cell lung cancer development.Frontiers in oncology · 2026Review
- Translating premalignant biology to accelerate non-small-cell lung cancer interception.Nature reviews. Cancer · 2025Review
- Assessment of MYC and TERT copy number variations in lung cancer using digital PCR.BMC research notes · 2023Article
- The impact of the lung EDRN-CVC on Phase 1, 2, & 3 biomarker validation studies.Cancer biomarkers : section A of Disease markers · 2022Article
- Cancer Immunoprevention: Current Status and Future Directions.Archivum immunologiae et therapiae experimentalis · 2021Review
- Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions.Nature communications · 2019Article
- Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia.Cancer research · 2018Article
- Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2017Article
- Detecting the Presence and Progression of Premalignant Lung Lesions via Airway Gene Expression.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- SOX2 Drives Bronchial Dysplasia in a Novel Organotypic Model of Early Human Squamous Lung Cancer.American journal of respiratory and critical care medicine · 2017Article
- Aneuploidy: a common and early evidence-based biomarker for carcinogens and reproductive toxicants.Environmental health : a global access science source · 2016Review
- Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma.Cancer prevention research (Philadelphia, Pa.) · 2016Article
- Interactions between household air pollution and GWAS-identified lung cancer susceptibility markers in the Female Lung Cancer Consortium in Asia (FLCCA).Human genetics · 2015Article
- Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial.Urology · 2014Article
- Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis.Cancer prevention research (Philadelphia, Pa.) · 2014Article
- Genetic variation in the TP63 gene is associated with lung cancer risk in the Han population.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Application of SNP microarrays to the genome-wide analysis of chromosomal instability in premalignant airway lesions.Cancer prevention research (Philadelphia, Pa.) · 2014Article
- Research status and funding trends of lung cancer biomarkers.Journal of thoracic disease · 2013Review
- SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling.Journal of molecular medicine (Berlin, Germany) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 3 countries.
Funding
Abstract
Lung carcinoma development is accompanied by field changes that may have diagnostic significance. We have previously shown the importance of chromosomal aneusomy in lung cancer progression. Here, we tested whether genomic gains in six specific loci, TP63 on 3q28, EGFR on 7p12, MYC on 8q24, 5p15.2, and centromeric regions for chromosomes 3 (CEP3) and 6 (CEP6), may provide further value in the prediction of lung cancer. Bronchial biopsy specimens were obtained by LIFE bronchoscopy from 70 subjects (27 with prevalent lung cancers and 43 individuals without lung cancer). Twenty six biopsies were read as moderate dysplasia, 21 as severe dysplasia and 23 as carcinoma in situ (CIS). Four-micron paraffin sections were submitted to a 4-target FISH assay (LAVysion, Abbott Molecular) and reprobed for TP63 and CEP 3 sequences. Spot counts were obtained in 30-50 nuclei per specimen for each probe. Increased gene copy number in 4 of the 6 probes was associated with increased risk of being diagnosed with lung cancer both in unadjusted analyses (odds ratio = 11, p<0.05) and adjusted for histology grade (odds ratio = 17, p<0.05). The most informative 4 probes were TP63, MYC, CEP3 and CEP6. The combination of these 4 probes offered a sensitivity of 82% for lung cancer and a specificity of 58%. These results indicate that specific cytogenetic alterations present in preinvasive lung lesions are closely associated with the diagnosis of lung cancer and may therefore have value in assessing lung cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.